Shopping Cart
Remove All
Your shopping cart is currently empty
BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $116 | - | In Stock | |
| 5 mg | $293 | - | In Stock | |
| 10 mg | $413 | - | In Stock | |
| 25 mg | $738 | - | In Stock | |
| 50 mg | $972 | - | In Stock | |
| 100 mg | $1,180 | - | In Stock | |
| 200 mg | $1,580 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $346 | - | In Stock |
| Description | BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity. |
| Targets&IC50 | ICAM1:78 nM |
| In vitro | BMS-688521 inhibits the specific adhesion of mouse splenocytes and a mouse ICAM-1 expressing cell line, b.END3, with an IC50 of 78 nM[1]. |
| In vivo | In BALB/c female mice, 6-8 weeks of age (OVA Lung Inflammation in Mice), BMS-688521 (1, 3, and 10 mg/kg; p.o.; BID for three days) exhibited significant inhibition of eosinophil accumulation at a dose of 1 mg/kg BID, with dose-dependent inhibition observed at 3 mg/kg and 10 mg/kg[1]. |
| Molecular Weight | 536.37 |
| Formula | C26H19Cl2N5O4 |
| Cas No. | 893397-44-9 |
| Smiles | O=C1[C@@]2([C@@H](CN(C2)C3=CC=C(C(O)=O)C=N3)C4=CC=C(C#N)C=C4)N(C)C(=O)N1C5=CC(Cl)=CC(Cl)=C5 |
| Relative Density. | 1.60 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (149.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 5 mg/mL (9.32 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.